Earnings And ValuationAnalysts reiterate a buy rating due to upside risks in earnings and valuation, with targets set for higher earnings per share and valuation ratios.
Product PerformanceUS Hips has recently outperformed the market, following the same trend as US Trauma last year, after the introduction of the short-stem CATALYSTEM hip platform.
Shareholder ValueA $500 million share buyback is planned, indicating confidence in the company's financial health and potential to return value to shareholders.